Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/8156
|
| Title: | Epstein-Barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan |
| Authors: | Coghill, AE;Hsu, WL;Pfeiffer, RM;Juwana, H;Yu, KJ;Lou, PJ;Wang, CP;Chen, JY;Chen, CJ;Middeldorp, JM;Hildesheim, A |
| Contributors: | National Institute of Cancer Research |
| Abstract: | BACKGROUND: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated cancer that is highly treatable when diagnosed early, with 5-year disease-free survival of approximately 90%. However, NPC is typically diagnosed at advanced stages, in which disease-free survival is <50%. There is, therefore, a need for clinical tools to assist in early NPC detection, particularly among high-risk individuals. METHODS: We evaluated the ability of anti-EBV IgA antibodies to detect incident NPC among high-risk Taiwanese individuals. NPC cases (N = 21) and age- and sex-matched controls (N = 84) were selected. Serum collected before NPC diagnosis was tested for ELISA-based IgA antibodies against the following EBV peptides: EBNA1, VCAp18, EAp138, Ead_p47, and VCAp18 + EBNA1 peptide mixture. The sensitivity, specificity, and screening program parameters were calculated. RESULTS: EBNA1 IgA had the best performance characteristics. At an optimized threshold value, EBNA1 IgA measured at baseline identified 80% of the high-risk individuals who developed NPC during follow-up (80% sensitivity). However, approximately 40% of high-risk individuals who did not develop NPC also tested positive (false positives). Application of EBNA1 IgA as a biomarker to detect incident NPC in a previously unscreened, high-risk population revealed that 164 individuals needed to be screened to detect 1 NPC and that 69 individuals tested positive per case detected. CONCLUSIONS: EBNA1 IgA proved to be a sensitive biomarker for identifying incident NPC, but future work is warranted to develop more specific screening tools to decrease the number of false positives. IMPACT: Results from this study could inform decisions about screening biomarkers and referral thresholds for future NPC early-detection program evaluations. |
| Date: | 2014-07 |
| Relation: | Cancer Epidemiology, Biomarkers and Prevention. 2014 Jul;23(7):1213-1219. |
| Link to: | http://dx.doi.org/10.1158/1055-9965.epi-13-1262 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1055-9965&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000345273700009 |
| Cited Times(Scopus): | http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84903986978 |
| Appears in Collections: | [陳振陽] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| PUB24769890.pdf | | 347Kb | Adobe PDF | 562 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
